Labcorp's (NYSE:LH) Q3 2026 sales beat estimates

What happened

Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9% year on year and above analysts' consensus of $3.76 billion. Non-GAAP profit was $4.78 per share, beating estimates, and the company raised full-year revenue guidance to $14.83 billion at the midpoint.

Confirmed

Global impact / market context

Beating sales and profit estimates while raising full-year guidance suggests Labcorp is winning more testing business and managing costs well. Higher revenue and a free cash flow margin of 10.8%, up from 7.9%, give the company more cash available to fund operations, debt payments, or investments.

Analyst inference

The results show steady demand for diagnostic testing, with organic revenue up 5.5%. Guidance raised to $14.83 billion at the midpoint, 0.6% above consensus, implies management expects the trend to continue, which supports profit expectations for healthcare diagnostics companies.

Analyst inference

What to watch

1. Full-year revenue guidance is now $14.83 billion at the midpoint, up from $14.77 billion, and adjusted EPS guidance rose to $18.50 at the midpoint. Confirmed
2. Watch whether free cash flow margin stays near 10.8%, because weaker cash conversion would reduce cash available for debt repayment, acquisitions, or shareholder returns. Analyst inference
3. Watch operating margin, which was 10.6% and flat year on year, because profit per sale must improve for earnings growth to continue at the current pace. Analyst inference

Evidence

• stockstory.org